Floridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway

Type Article
Date 2008-09
Language English
Author(s) Courtois Anthony1, 2, Simon-Colin Christelle2, Boisset Claire2, Berthou Christian1, Deslandes Eric3, Guezennec Jean2, Bordron Anne1
Affiliation(s) 1 : Brest Univ Hosp, Cellular Therapy & Immunobiol Canc Lab, EA2216, Brest, France.
2 : IFREMER, Ctr Brest, Biotechnol & Marine Mol Lab, Brest, France.
3 : Univ Western Brittany, European Inst Marine Studies, LEBHAM, Brest, France.
Source Marine drugs (1660-3397) (Molecular Diversity Preservation International), 2008-09 , Vol. 6 , N. 3 , P. 407-417
DOI 10.3390/md20080019
WOS© Times Cited 13
Keyword(s) Complement system, Immunomodulation, Marine algae, Alpha galactosyl glycerol
Abstract Many biological properties of algae have been found to have useful applications in human health, particularly in the fields of oncology and immunology. Floridoside, extracted from the red alga Mastocarpus stellatus, has a structure similar to the xenoantigen Gal alpha 1-3 Gal. This xenoantigen has been described to induce a high immune response in human xenografts and is mediated by natural anti-gal antibodies that activate the classical complement pathway. Based on this property, we analyzed the potential activities of floridoside on the immune system. We demonstrated that floridoside activates a complement cascade via the classical complement pathway, through the recruitment and activation of natural IgM. This algal molecule could represent an important step in the development of a potent new anticomplementary agent for use in therapeutic complement depletion.
Full Text
File Pages Size Access
publication-6248.pdf 10 80 KB Open access
Top of the page

How to cite 

Courtois Anthony, Simon-Colin Christelle, Boisset Claire, Berthou Christian, Deslandes Eric, Guezennec Jean, Bordron Anne (2008). Floridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway. Marine drugs, 6(3), 407-417. Publisher's official version : https://doi.org/10.3390/md20080019 , Open Access version : https://archimer.ifremer.fr/doc/00000/6248/